Multimerization via Its Myosin Domain Facilitates Nuclear Localization and Inhibition of Core Binding Factor (CBF) Activities by the CBFβ-Smooth Muscle Myosin Heavy Chain Myeloid Leukemia Oncoprotein
Open Access
- 1 December 2002
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 22 (23) , 8278-8291
- https://doi.org/10.1128/mcb.22.23.8278-8291.2002
Abstract
In CBFβ-SMMHC, core binding factor beta (CBFβ) is fused to the α-helical rod domain of smooth muscle myosin heavy chain (SMMHC). We generated Ba/F3 hematopoietic cells expressing a CBFβ-SMMHC variant lacking 28 amino acids homologous to the assembly competence domain (ACD) required for multimerization of skeletal muscle myosin. CBFβ-SMMHC(ΔACD) multimerized less effectively than either wild-type protein or a variant lacking a different 28-residue segment. In contrast to the control proteins, the ΔACD mutant did not inhibit CBF DNA binding, AML1-mediated reporter activation, or G1 to S cell cycle progression, the last being dependent upon activation of CBF-regulated genes. We also linked the CBFβ domain to 149 or 83 C-terminal CBFβ-SMMHC residues, retaining 86 or 20 amino acids N-terminal to the ACD. CBFβ-SMMHC(149C) multimerized and slowed Ba/F3 proliferation, whereas CBFβ-SMMHC(83C) did not. The majority of CBFβ-SMMHC and CBFβ-SMMHC(149C) was detected in the nucleus, whereas the ΔACD and 83C variants were predominantly cytoplasmic, indicating that multimerization facilitates nuclear retention of CBFβ-SMMHC. When linked to the simian virus 40 nuclear localization signal (NLS), a significant fraction of CBFβ-SMMHC(ΔACD) entered the nucleus but only mildly inhibited CBF activities. As NLS-CBFβ-SMMHC(83C) remained cytoplasmic, we directed the ACD to CBF target genes by linking it to the AML1 DNA binding domain or to full-length AML1. These AML1-ACD fusion proteins did not affect Ba/F3 proliferation, in contrast to AML1-ETO, which markedly slowed G1 to S progression dependent upon the integrity of its DNA-binding domain. Thus, the ACD facilitates inhibition of CBF by mediating multimerization of CBFβ-SMMHC in the nucleus. Therapeutics targeting the ACD may be effective in acute myeloid leukemia cases associated with CBFβ-SMMHC expression.Keywords
This publication has 61 references indexed in Scilit:
- c-Myc Overcomes Cell Cycle Inhibition by CBFβ-SMMHCCancer Biology & Therapy, 2002
- The Tip of the Coiled-coil Rod Determines the Filament Formation of Smooth Muscle and Nonmuscle MyosinJournal of Biological Chemistry, 2001
- TrueLeukemia, 1999
- The Core Binding Factor (CBF) α Interaction Domain and the Smooth Muscle Myosin Heavy Chain (SMMHC) Segment of CBFβ-SMMHC Are Both Required to Slow Cell ProliferationJournal of Biological Chemistry, 1998
- The chimeric protein, PEBP2β/CBFβ-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activationOncogene, 1998
- The protooncogene product, PEBP2β/CBFβ, is mainly located in the cytoplasm and has an affinity with cytoskeletal structuresOncogene, 1997
- A 29 residue region of the sarcomeric myosin rod is necessary for filament formation 1 1Edited by J. KarnJournal of Molecular Biology, 1997
- Myosin filament structure in vertebrate smooth muscle.The Journal of cell biology, 1996
- AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver HematopoiesisCell, 1996
- IL3-dependent mouse clones that express B-220 surface antigen, contain ig genes in germ-line configuration, and generate B lymphocytes in vivoCell, 1985